235 related articles for article (PubMed ID: 10668477)
1. Progress in cancer chemoprevention.
Kelloff GJ; Crowell JA; Steele VE; Lubet RA; Boone CW; Malone WA; Hawk ET; Lieberman R; Lawrence JA; Kopelovich L; Ali I; Viner JL; Sigman CC
Ann N Y Acad Sci; 1999; 889():1-13. PubMed ID: 10668477
[TBL] [Abstract][Full Text] [Related]
2. New agents for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet RA; Doody LA; Malone WF; Hawk ET; Sigman CC
J Cell Biochem Suppl; 1996; 26():1-28. PubMed ID: 9154166
[TBL] [Abstract][Full Text] [Related]
3. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents.
Kelloff GJ; Crowell JA; Steele VE; Lubet RA; Malone WA; Boone CW; Kopelovich L; Hawk ET; Lieberman R; Lawrence JA; Ali I; Viner JL; Sigman CC
J Nutr; 2000 Feb; 130(2S Suppl):467S-471S. PubMed ID: 10721931
[TBL] [Abstract][Full Text] [Related]
4. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
5. Strategy and planning for chemopreventive drug development: clinical development plans II.
Kelloff GJ; Crowell JA; Hawk ET; Steele VE; Lubet RA; Boone CW; Covey JM; Doody LA; Omenn GS; Greenwald P; Hong WK; Parkinson DR; Bagheri D; Baxter GT; Blunden M; Doeltz MK; Eisenhauer KM; Johnson K; Knapp GG; Longfellow DG; Malone WF; Nayfield SG; Seifried HE; Swall LM; Sigman CC
J Cell Biochem Suppl; 1996; 26():54-71. PubMed ID: 9154168
[TBL] [Abstract][Full Text] [Related]
6. Cancer chemoprevention. Part 1: Retinoids and carotenoids and other classic antioxidants.
Singh DK; Lippman SM
Oncology (Williston Park); 1998 Nov; 12(11):1643-53, 1657-8; discussion 1659-60. PubMed ID: 9834941
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer.
Decensi A; Costa A
Eur J Cancer; 2000 Apr; 36(6):694-709. PubMed ID: 10762741
[TBL] [Abstract][Full Text] [Related]
8. Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents.
Greenwald P; Kelloff GJ; Boone CW; McDonald SS
Cancer Epidemiol Biomarkers Prev; 1995; 4(7):691-702. PubMed ID: 8672984
[TBL] [Abstract][Full Text] [Related]
9. Chemopreventive drug development: perspectives and progress.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Sigman CC
Cancer Epidemiol Biomarkers Prev; 1994; 3(1):85-98. PubMed ID: 8118391
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of prostate cancer: concepts and strategies.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovitch L; Malone WA; Crowell JA; Sigman CC
Eur Urol; 1999; 35(5-6):342-50. PubMed ID: 10325487
[TBL] [Abstract][Full Text] [Related]
11. Cancer chemoprevention by targeting the epigenome.
Huang J; Plass C; Gerhauser C
Curr Drug Targets; 2011 Dec; 12(13):1925-56. PubMed ID: 21158707
[TBL] [Abstract][Full Text] [Related]
12. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovich L; Malone WA; Crowell JA; Higley HR; Sigman CC
Urology; 2001 Apr; 57(4 Suppl 1):46-51. PubMed ID: 11295594
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic considerations in chemopreventive drug development.
Kelloff GJ; Boone CW; Steele VE; Fay JR; Lubet RA; Crowell JA; Sigman CC
J Cell Biochem Suppl; 1994; 20():1-24. PubMed ID: 7616736
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of cancer.
Szarka CE; Grana G; Engstrom PF
Curr Probl Cancer; 1994; 18(1):6-79. PubMed ID: 8005001
[TBL] [Abstract][Full Text] [Related]
16. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
Reddy BS
Environ Mol Mutagen; 2004; 44(1):26-35. PubMed ID: 15199544
[TBL] [Abstract][Full Text] [Related]
17. Cancer chemoprevention agent development strategies for genistein.
Steele VE; Pereira MA; Sigman CC; Kelloff GJ
J Nutr; 1995 Mar; 125(3 Suppl):713S-716S. PubMed ID: 7884556
[TBL] [Abstract][Full Text] [Related]
18. Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat.
Wargovich MJ; Chen CD; Jimenez A; Steele VE; Velasco M; Stephens LC; Price R; Gray K; Kelloff GJ
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):355-60. PubMed ID: 9162301
[TBL] [Abstract][Full Text] [Related]
19. Cancer chemoprevention and nutriepigenetics: state of the art and future challenges.
Gerhauser C
Top Curr Chem; 2013; 329():73-132. PubMed ID: 22955508
[TBL] [Abstract][Full Text] [Related]
20. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
